Hepatitis E virus genotype 3 microbiological surveillance by the Spanish Reference Laboratory: geographic distribution and phylogenetic analysis of subtypes from 2009 to 2019

Milagros Muñoz-Chimeno¹, Silvia Bartúren¹, Maira Alejandra García-Lugo¹, Lucía Morago¹, Álvaro Rodríguez¹, Juan Carlos Galán²-³, Alfredo Pérez-Rivilla⁴, Mercedes Rodríguez⁵, Rosario Millán⁶, Manuel del Álamo⁷, Roberto Alonso⁸, Laura Molina⁹, Aitziber Aguinaga¹⁰, Ana Avellón¹

¹. Hepatitis Unit, National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain
². Servicio de Microbiología, Hospital Universitario Ramón y Cajal and Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain
³. CIBERESP, Madrid, Spain
⁴. Hospital Universitario 12 de Octubre, Madrid, Spain
⁵. Hospital Universitario Central de Asturias, Grupo de Microbiología Traslacional (ISPA) Oviedo, Asturias, Spain
⁶. Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
⁷. Hospital Universitario Severo Ochoa, Leganés, Madrid, Spain
⁸. Hospital General Universitario Gregorio Marañón, Madrid, Spain
⁹. Hospital Universitario de Fuenlabrada, Madrid, Spain
¹⁰. Complejo Hospitalario de Navarra, Pamplona, Navarra, Spain

Correspondence: Ana Avellón (aavellon@isciii.es)

Citation style for this article:
Muñoz-Chimeno Milagros, Bartúren Silvia, García-Lugo Maite Alejandra, Morago Lucía, Rodríguez Álvaro, Galán Juan Carlos, Pérez-Rivilla Alfredo, Rodríguez Mercedes, Millán Rosario, del Álamo Manuel, Alonso Roberto, Molina Laura, Aguinaga Aitziber, Avellón Ana. Hepatitis E virus genotype 3 microbiological surveillance by the Spanish Reference Laboratory: geographic distribution and phylogenetic analysis of subtypes from 2009 to 2019. Euro Surveill. 2022;27(23):pii=2100542. https://doi.org/10.2807/1560-7917.ES.2022.27.23.2100542

Article submitted on 31 May 2021 / accepted on 21 Jan 2022 / published on 09 Jun 2022

Background: Hepatitis E virus genotype 3 (HEV-3) is widely distributed throughout Europe, with incidence of infections increasing in many countries. Belgium, Bulgaria, France, Germany, Italy, the Netherlands and the United Kingdom have reported the distribution of HEV-3 subtypes in cohorts of patients with hepatic disease. Aim: To describe the distribution of the HEV-3 subtypes in Spain at national and autonomous community (AC) levels between 2009 and 2019. The study was also extended to Andorra. Methods: Of 5,197 samples received by the National Reference Laboratory during the study, 409 were HEV-RNA-positive. Among these, 294 (71.9%) were further typed based on an ORF2 sequence fragment, or, for a subset of 74, based on the full-coding genome sequence. Results: HEV-3 was detected in 291 samples. The dominant subtype in Spain was HEV-3f (88.3%; 257/291), which occurred in all ACs, with no change in detection level over time. Within this subtype, three subclusters were characterised: HEV-3f-B, HEV-3f-A1 and HEV-3f-A2. The second most common HEV subtype was the recently described HEV-3m (7%; 21/291), which occurred in all ACs, with no change in detection level over time. Within this subtype, three subclusters were characterised: HEV-3m-B, HEV-3m-A1 and HEV-3m-A2. The second most common HEV subtype was the recently described HEV-3m (7%; 21/291), with two subclusters identified: HEV-3m-A, which has been known since 2010, and HEV-3m-B, since 2014. The third most encountered subtype was HEV-3c (4.1%; 12/291), with a frequency not increasing over time, unlike observations in some European countries.

Conclusion: The importance of the surveillance of HEV-3 subtype and subcluster circulation is yet to be assessed. This surveillance together with the comprehensive epidemiological characterisation of clinical cases, could support the identification of sources of transmission and the establishment of control measures nationally and internationally.

Introduction: Hepatitis E virus (HEV) infection makes up a considerable portion of acute hepatic disease. The number of new HEV infections acquired in the European Union/European Economic Area (EU/EEA) is growing [1]. HEV belongs to the Hepeviridae family, and its Orthohepevirus A genus includes viruses that infect humans, pigs, boars, rabbits and camels, among others [2]. Eight genotypes have been described so far, five of which (HEV-1, 2, 3, 4 and 7) infect humans [3]. Epidemiology and transmission of HEV follow two distinct patterns with different characteristics. Genotypes 1 and 2 affect only to humans and cause epidemics in lower-middle income countries through faecal–oral transmission. Genotypes 3 and 4 can both cause zoonosis and can be detected in humans and animals worldwide. Domestic pigs and wild boars are the most important animal reservoirs for these genotypes and...
the main source of human infection after meat consumption [4]. Genotype 7 cases are very rare.

In 2014, HEV-3 variants were classified into two major clades named 3abchij and 3efg [5], which both included several genetic subtypes. A third clade corresponding to the 3a subtype had, however, been described in 2009, with strains detected in infected rabbits [6]. According to Smith et al. in 2016 [3], the genetic distance between whole genome sequences (WGS) of viruses divides HEV-3 genotypes into subtypes 3a, 3b, 3c, 3d, 3e, 3f, 3g, 3h, 3i and 3j. In 2017 and 2018, two new HEV-3 subtypes were identified: HEV-3k [7] and HEV-3l [8]. In 2020, Smith et al. [9] updated reference sequences, whereby an additional subtype, HEV-3m was proposed. The update was based on previously published sequences from Spain [10] and France [11], however, some sequences still remained unassigned. Recently, an automated partition of a maximum likelihood phylogenetic tree and distance analysis method

Potential HEV-3f-A1, HEV-3f-A2 and HEV-3f-B subclusters are shown by red, blue and green lines, respectively. Sequences obtained in this study are indicated by coloured circles with colour according to year of sampling. Reference sequences of HEV genotypes 1, 2, 3, 4, 5, 6, 7 and 8 were included in the analysis. Genbank accession numbers are indicated on the tree leaves. Bootstrap values indicating the number of repetitions of the tree with the showed topology are included in the tree nodes defining clades, genotypes, subtypes, clusters and subclusters.
suggested the existence of several new subtypes, enabling to classify some of the previously unassigned WGS [12].

The distribution of HEV subtypes in cohorts of patients with hepatic disease has, to our knowledge, been studied in only a few European countries: Belgium [13,14], Bulgaria [15], France [11,16], Germany [17,18], Italy [19,20], the Netherlands [21] and the United Kingdom (UK) [5,22]. In the case of Spain, there is limited information about the distribution of HEV-3 subtypes in humans. All HEV subtypes obtained in a retrospective study of patients in 2000–2004 and 2007–2008 [23] and in liver donors [24] were HEV-3f. In Spanish pig populations, several studies have shown that HEV-3 has long been present, and in 2017, subtypes HEV-3f and HEV-3m were detected in two pig liver samples [25]. HEV-3m has also been found in Spanish wild boar [26].

The present work aims to characterise HEV genotypes, subtypes and main subclusters found in Spain from 2009 to 2019 by phylogenetic and p-distance analyses. Data from Andorra are also analysed. The temporal distribution of subtypes/subclusters throughout the study period is also presented, as well as their geographical occurrence in the different autonomous communities (ACs) of Spain, as well as in Andorra.

Methods

Samples

From 2009 to 2019, the National Centre of Microbiology, Instituto de Salud Carlos III, Majadahonda (Madrid), Spain, acting as HEV reference laboratory, received 5,197 serum samples for HEV RNA detection. These originated from public hospitals of all ACs of Spain. Four samples from Andorra were also included. Samples had been sent to the reference laboratory for confirmation of previous positive anti-HEV results or confirmation of primary HEV diagnosis after negative findings for hepatitis A, B and C viruses. HEV-RNA-positive samples were included in the study.

Ribonucleic acid extraction and retro-transcription

RNA was extracted automatically from 200-µL serum samples with the Magna Pure LC 2.0 System (Roche Diagnostics, Germany) following the total NA protocol. Complementary DNA (cDNA) was obtained by reverse-transcription with random hexamers using a Transcription First Strand cDNA Synthesis kit (Roche Diagnostics, Mannheim, Germany), following the manufacturer’s recommendations.

Amplification and sequencing

A 459-bp fragment of the HEV open reading frame (ORF)2 region was amplified by nested PCR, using as template a 916-bp amplicon obtained from a primary PCR on the cDNA. For both the primary and nested PCRs, 5 µL of DNA were used in both a primary and 50-µL-reaction volume containing PCR Master Mix and RNase-free water (Promega, Madison, WI, United States (US)). The primers for the primary PCR were 5’-GAGYGTGTYATCCCCAGTGGAGGCG-3’ (forward) and 5’-CCTTRGTGCTRTCAGGYCCTCAA-3’ (reverse), and the PCR temperature profile comprised 4 min at 94°C (initial denaturation), then 40 cycles including 1 min at 94°C (denaturation), 1 min at 57°C (annealing) and 1 min at 72°C (elongation), followed by a final elongation for 5 min at 72°C. For the nested PCR, the primers were 5’-GGTTGSCGCYAGGAGGAGGCC-3’ (forward) and 5’-CCYTTRTCYTGTGCTGYGCAACTC-3’ (reverse) and the temperature profile was 2 min at 94°C (initial denaturation), then 35 cycles including 1 min at 94°C (denaturation), 1 min at 57°C (annealing) and 1 min at 72°C (elongation), followed by a final elongation for 5 min at 72°C. PCR products were separated by electrophoresis on 2% agarose gels in Tris-borate- ethylenediaminetetraacetic acid (TBE) buffer at a final concentration of 0.5× and stained using Biotium GelRed (Hayward, CA, US).

Amplification products were purified with Illustra ExoProStar 1-STEP (VWR International Eurolab S.L., Radnor, Pennsylvania, US). Sense and antisense DNA strands were both sequenced by the Sanger method. For 74 clinical serum samples, a full HEV-3 coding genome was respectively obtained through 12 overlapping nested PCRs, mainly as described previously [10].

Phylogenetic analysis and sequence identification

Sequence alignment, p-distances calculations and phylogenetic trees were derived using the Molecular Evolutionary Genetics Analysis (MEGA) 7.0 package (https://www.megasoftware.net/). A 411-bp fragment (5,960–6,371 according to the sequence with accession number KU513561) was used for ORF2 analysis. The full-coding genomes, excluding the hypervariable region (HVR), ranged from 6,844 to 7,124 bp. Phylogenetic trees were derived by a maximum likelihood (ML) approach using the general time-reversible model (GTR + G + I) according to the substitution model estimated with jModelTest (PhyML 3.0 programme; http://atgc.lirmm.fr/phylm/), based on the Akaia information criterion. Support for tree nodes was assessed by bootstrap values (BT) based on 1,000 replicates.

The reference sequences used were those updated by Smith et al. [9], with the following GenBank accession numbers: M73218 (HEV-1), KX578717 (HEV-2), AF082843 (HEV-3a), AP003430 (HEV-3b), FJ705359 (HEV-3c), AB248521 (HEV-3e), AB369687 (HEV-3f), AF455784 (HEV-3g), JQ013794 (HEV-3h), FJ998008 (HEV-3i), AY115488 (HEV-3j), FJ906895 (HEV-3k), KU513561 (HEV-3-Japan), AB369689 (HEV-3k), KJ953664 (HEV-3l), LC260517 (HEV-3-Italy), MF959764 (HEV-3Italy), MH35764 (HEV-3-Italy), KP294371 (HEV-3Germany), AB197673 (HEV-4), AB573345 (HEV-5), AB602441 (HEV-6), KJ496143 (HEV-7), and KX387865
HEV-3: hepatitis E virus genotype 3.

A. Potential HEV-3f-A1, HEV-3f-A2 and HEV-3f-B subclusters are shown by red, blue and green lines, respectively. Countries (flags) and year of detection are shown next to each subcluster name. The sizes of the flags reflect the number of sequences from each country (smallest-sized flag: 1-2 sequences; medium-size flag: 3-7 sequences; largest-size flag: ≥ 8 sequences). Sequences of animal origin are shown with an asterisk. The 65 sequences from Spain analysed in this study are indicated by coloured circles, with colour according to the year of sampling. Genbank accession numbers of sequences used for the phylogenetic analysis are indicated on the tree leaves. Bootstrap values indicating the number of repetitions of the tree with the showed topology are included in the tree nodes defining clades, genotypes, subtypes, clusters and subclusters.

B. Histogram comparing the frequencies of p-distance values in intra-group (light blue) vs inter-group (dark blue) sequence comparisons.
(HEV-8). Sequences obtained in this study were assigned GenBank accession numbers MZ272478–MZ272697 and MZ289076–MZ289149.

**Statistical analysis**

Group differences between categories of qualitative variables were investigated with chi-squared tests. Values of \( p < 0.05 \) were considered to be significant.

**Results**

**Total number of analysed sequences**

From the 5,197 total samples received by the HEV reference laboratory, 409 (7.87%) were positive for HEV RNA (Supplementary Table S1, Representativeness of obtained sequences from yearly studies samples). From the latter, 294 sequences were respectively obtained (representing 71.9% from the total RNA positive), with only partial-ORF2 sequences for 220 and full-coding (representing 71.9% from the total RNA positive), with the latter, 294 sequences were respectively obtained sequences from yearly studies samples). From the full-coding genome sequence analysis illustrated in Figure 1, we observed potential subclusters defining subtypes (Supplementary Table S2, Similar genetic p-distances to reference sequences in weaker, though still sufficient, bootstrap support, and a HEV-3f-B subcluster (BT99). The average and range of the intergroup p-distances in HEV-3m-A and HEV-3m-B were 0.014 (range: 0.000–0.024) and 0.062 (range: 0.011–0.088), respectively, and the average intergroup distance was 0.095 (range: 0.092–0.099).

For further analyses of HEV-3, we consider EU360977, MF444091 (Figure 2) and MF444030 (Supplementary Figure S2) as reference sequences for potential subclusters of HEV-3f-B, HEV-3f-A2 and HEV-3m-B, respectively, as they were the first to be published in the GenBank database.

**Temporal and geographical distribution of hepatitis E virus genotypes**

A total of 294 sequences were genotyped using the 411-bp ORF2 fragment (Figure 3). Three samples detected in 2014, 2018 and 2019 were HEV-1 (subtype 1g) (3/294; 1.0%). The remaining samples were HEV-3 (291/294; 99.0%).

HEV-3f was the most prevalent subtype (257/291; 88.3%), followed by HEV-3m (21/291; 7.2%) and HEV-3c (12/291; 4.1%). One sequence (MZ272662), found inside the 3abjk clade and obtained in 2019 in Andalusia, did not group with any previously described subtype reference sequence (the closest being HEV-3b, with a p-distance of 0.110).

HEV-3f-A1, HEV-3f-A2 and HEV-3f-B accounted for 212 (72.8%), 42 (14.4%) and two (0.7%) of the 291 HEV-3f positive samples, respectively. One sequence from 2019 (MZ272695) did not group with any of the three described HEV-3f groups (Figure 3), but was closest to HEV-3f-A1, with a p-distance of 0.076.

The temporal and geographical distributions of the subtypes and subclusters are shown in Table 1 and Table 2. The analysis of the distribution of subtypes and subclades over time showed that HEV-3m-B was first detected in Spain in 2014 and HEV-3f-B in 2017. No statistical differences were observed for any of the HEV subtypes or subclusters when comparing the periods 2009–2013 and 2014–2019 (p>0.05).

The geographical location of patients infected with HEV-3 was known for 289 samples (Figure 4 and Table 2). All the ACs of Spain were represented, including the Balearic and Canary Islands. However, no sequences were available from the Autonomous Cities of North Africa (Ceuta and Melilla). Data from Andorra were also included in the dataset with a total of two HEV-3f
Figure 3
Phylogenetic analysis of 294 ORF2 fragment genetic sequences of HEV recovered in Spain, including two sequences of Andorra, 2013–2019 (n = 323 sequences in the tree)

HEV: hepatitis E virus; ORF2: open reading frame 2.

Potential HEV-3f-A1, HEV-3f-A2 and HEV-3f-B subclusters are shown with red, blue and green lines respectively. The 294 sequences obtained in this study are indicated with coloured circles, with colour according to year of sampling. Reference sequences of HEV genotypes 1, 2, 3, 4, 5, 6, 7 and 8 were included in the analysis. Genbank accession numbers of sequences used for the phylogenetic analysis are indicated on the tree leaves. Bootstrap values indicating the number of repetitions of the tree with the showed topology are included in the tree nodes defining clades, genotypes, subtypes, clusters and subclusters.
positive samples over the study period. Examination of the distribution of geographical subtypes showed that the HEV-3f subtype was widely distributed throughout Spain but was most frequent in the north of the country (p = 0.000). HEV-3c was present in some of the ACs, being most prevalent in those in the east (p = 0.005). We found no differences in the distribution of the HEV-3f subclusters. The HEV-3m subtype was reported in the centre, north and south of the country, but no cases were found in the east.

### Discussion

Hepatitis E is not notifiable in Spain and consequently temporal trends of the incidence of cases are not available. Information on HEV from the Spanish National Reference Laboratory is used for microbiological surveillance and has contributed to work assessing the epidemiological situation of HEV in humans in Europe [1]. In the current work, 71.9% of samples testing positive for HEV RNA in the reference laboratory between 2009 and 2019 were further characterised by sequencing, phylogenetic or genetic p-distance analyses. The data obtained were used to assess the temporal and geographical distribution of HEV-3 subtypes in Spain, both nationally and at the AC level.

While 71.9% of HEV-RNA-positive samples were typed, the annual proportions of sequenced positive samples appeared to be higher in the years of prospective investigations (2018 and 2019) than in the earlier years of the study. Moreover, between the beginning and the end of the study period, there seemed to be an increase in the proportions of positive samples sequenced.

Although HEV WGS are obtainable by Sanger sequencing [10,27] or next-generation sequencing (NGS) after enrichment by amplification, WGS are not routinely used for HEV typing for technical reasons. Here, 294 HEV-positive samples were analysed based on the sequence of an ORF2 fragment. To avoid non-congruent subtyping, HEVnet 2019 recommendations to employ a minimum ORF2 sequence length of 300 nt were followed [28], and the ORF2 fragment used was 411 bp long, which is more than that in other European studies [12,15,17,19,21]. Moreover, to check the reliability of this fragment for typing, a subset of 74 study samples was subjected to characterisation both based on the fragment data and based on the full-coding genome sequence data. As the results produced by the two approaches were similar, the fragment-based method was deemed adequate for defining not only subtypes, but also subclusters.

HEV-3f was found to be the dominant subtype in Spain, accounting for 88.3% of HEV-3-typed viruses in the period from 2009 to 2019, with no significant change in frequency during that time. The subtype was present in all Spanish ACs. HEV-3f was likewise the main subtype during a similar period in Belgium (50.7%) [14], south-western France (73.6%) [16] and Italy [19], occurring also, but not as the most prevalent subtype, in Germany, the Netherlands, the UK, and Bulgaria [5,15,17,21]. For Bulgaria, between 2013 and 2015, it was reported that 24% of the subtyped samples of patients with acute hepatitis E corresponded to HEV-3f, while the majority was represented by HEV-3e (62%) [15].

Three subclusters of viruses were identified within HEV-3f in the current study, namely HEV-3f-A1, A2, and B. These are described through phylogenetic and p-distance analyses of full-coding genome sequence. HEV-3f-A1 and HEV-3f-A2 have been present in Spain since 2009–2010. Indeed, HEV-3f-A2 seems to be a mainly Spanish subcluster, with inside, only three non-Spanish sequences, collected from France in 2012, 2015 and 2016 according to the phylogenetic analysis. By contrast, HEV-3f-A1 occurs throughout Europe (Spain, 2009–2010).

#### Table 1

| Subtype      | Year | Total 2009–2019 n | % | Periods 2009–2013 n | % | 2014–2019 n | % | p value |
|--------------|------|-------------------|---|---------------------|---|-------------|---|---------|
| HEV-3abjk    | 2009 | 0                 | 0 | 2010                | 0 | 2011        | 0 | 2012    | 0 | 2013    | 0 | 2014    | 0 | 2015    | 0 | 2016    | 0 | 2017    | 0 | 2018    | 0 | 2019    | 1 | 3 | 0.3 | 2010 | 0 | 0 | 0.4 | NA |
| HEV-3c       | 2009 | 0                 | 0 | 2010                | 0 | 2011        | 0 | 2012    | 0 | 2013    | 0 | 2014    | 0 | 2015    | 0 | 2016    | 0 | 2017    | 0 | 2018    | 0 | 2019    | 0 | 0 | 0.4 | 2010 | 0 | 0 | 0.4 | NA |
| HEV-3f       | 2009 | 1                 | 3 | 2010                | 11 | 2011        | 12 | 2012    | 7 | 2013    | 30 | 2014    | 17 | 2015    | 32 | 2016    | 46 | 2017    | 52 | 2018    | 46 | 2019    | 257 | 88.3 | 34 | 85.0 | 223 | 88.8 | 0.48 |
| HEV-3f-A1    | 2009 | 1                 | 1 | 2010                | 10 | 2011        | 6 | 2012    | 11 | 2013    | 26 | 2014    | 38 | 2015    | 48 | 2016    | 41 | 2017    | 213 | 73.2 | 30 | 75.0 | 183 | 72.9 | 0.25 |
| HEV-3f-A2    | 2009 | 0                 | 2 | 2010                | 1 | 2011        | 1 | 2012    | 3 | 2013    | 6 | 2014    | 7 | 2015    | 4 | 2016    | 4 | 2017    | 42 | 14.4 | 4 | 10.0 | 38 | 15.1 | 0.39 |
| HEV-3f-B     | 2009 | 0                 | 0 | 2010                | 0 | 2011        | 0 | 2012    | 0 | 2013    | 0 | 2014    | 0 | 2015    | 0 | 2016    | 0 | 2017    | 0 | 2018    | 0 | 2019    | 1 | 0 | 0.1 | 2010 | 0 | 0 | 0.4 | 2010 |
| HEV-3m       | 2009 | 0                 | 0 | 2010                | 0 | 2011        | 0 | 2012    | 0 | 2013    | 0 | 2014    | 0 | 2015    | 0 | 2016    | 0 | 2017    | 0 | 2018    | 0 | 2019    | 0 | 0 | 0.4 | 2010 | 0 | 0 | 0.4 | 2010 |
| HEV-3m-A     | 2009 | 0                 | 0 | 2010                | 1 | 2011        | 0 | 2012    | 0 | 2013    | 3 | 2014    | 2 | 2015    | 3 | 2016    | 1 | 2017    | 1 | 2018    | 1 | 2019    | 21 | 7.2 | 3 | 7.5 | 18 | 7.2 | 0.94 |
| HEV-3m-B     | 2009 | 0                 | 0 | 2010                | 0 | 2011        | 0 | 2012    | 0 | 2013    | 0 | 2014    | 0 | 2015    | 0 | 2016    | 0 | 2017    | 0 | 2018    | 0 | 2019    | 0 | 0 | 0.4 | 2010 | 0 | 0 | 0.4 | 2010 |
| Total        | 2009 | 1                 | 1 | 2010                | 11 | 2011        | 1 | 2012    | 3 | 2013    | 10 | 2014    | 3 | 2015    | 3 | 2016    | 0 | 2017    | 0 | 2018    | 0 | 2019    | 291 | 100 | 40 | 100 | 251 | 100 | NA |

HEV-3: hepatitis virus genotype 3; NA: not applicable.
### Table 2
HEV-3 subtype distribution in different geographical areas, Spain and Andorra, 2009–2019 (n = 289 samples)

| Subtype     | Subcluster | Spanish autonomous communities<sup>b</sup> | AD | Total | Geographical groups | Centre<sup>c</sup> | East<sup>d</sup> | North<sup>e</sup> | South<sup>f</sup> |
|-------------|------------|-------------------------------------------|----|-------|---------------------|-------------------|----------------|----------------|----------------|
| HEV-3abies |            |                                           | 0  | 0     | 0                   | 0.0              | 0.0           | 0.0            | 1.3            |
| HEV-3c     |            |                                           | 0  | 1     | 5                   | 6.0              | 4.0           | 1.2            | 1.3            |
| HEV-3f     |            |                                           | 8  | 8     | 109                 | 255              | 88.2         | 130            | 75.0           |
| HEV-3f-A1 |            |                                           | 6  | 7     | 85                  | 211              | 73.0         | 102            | 19.0           |
| HEV-3f-A2 |            |                                           | 2  | 1     | 23                  | 42               | 14.5         | 27             | 7.4            |
| HEV-3f-B   |            |                                           | 0  | 0     | 1                   | 2                | 0.7          | 1.0            | 0.0            |
| HEV-3m     |            |                                           | 1  | 2     | 11                  | 21               | 7.3          | 15             | 5.2            |
| HEV-3m-A   |            |                                           | 1  | 2     | 3                   | 11               | 3.8          | 6.0            | 1.2            |
| HEV-3m-B   |            |                                           | 0  | 0     | 8                   | 10               | 3.5          | 9.0            | 0.0            |
| Total      |            |                                           | 9  | 11    | 125                 | 289              | 100          | 151            | 81.0           |

AD: Andorra.

<sup>a</sup>Among 291 samples positive for HEV-3, 289 were accompanied by data on the autonomous community where the patient was located.

<sup>b</sup>AN: Andalusia; AR: Aragon; AS: Principality of Asturias; CB: Cantabria; CL: Castile and León; CM: Castile-La Mancha; CN: Canary Islands; CT: Catalonia; EX: Extremadura; GA: Galicia; HEV-3: hepatitis virus genotype 3; IB: Balearic Islands; MC: Region of Murcia; MD: Community of Madrid; NC: Chartered Community of Navarre; PV: Basque Country; RI: La Rioja; VC: Valencian Community.

<sup>c</sup>Centre: CM, CL, MD and EX.

<sup>d</sup>East: AR, IB, CT, VC and MC. AD data were also included in the ‘East’ group as this country locates to the east of Spain.

<sup>e</sup>North: AS, CB, NC, GA, RI and PV.

<sup>f</sup>South: AN and CN.
Figure 4
(a) Geographical distribution of samples testing positive for hepatitis E virus genotype 3 according to subtype and (b) temporal distribution with further stratification of subtypes at the subcluster level, Spain and Andorra, 2009–2019 (n = 289 samples)"
Germany and France) and Asia (Japan and Thailand), where it has been detected in human and pigs. A study from Italy described HEV-3f (typed by us as HEV-3f-A1, data not shown) and HEV-3e as producing outbreaks in this country in 2019 [20]. HEV-3f-B is a well-defined subcluster with sequences derived mainly from pigs in Sweden and Denmark, and it also includes sequences originating from human infections in Germany and Singapore.

We found the recently described HEV-3m in Spain [9]. This subtype appears to have been circulating in Spain since at least 2010 [10] at a frequency of more than 7% since then, making it the second most common HEV subtype. HEV-3m has been reported occasionally in France, and the UK [5,11,29] in humans, and described in a wild boar in Spain [26]. It has also been suggested that this subtype is associated with the consumption of contaminated meat containing wild boar [30]. Two different subclusters within HEV-3m were identified in the current study: HEV-3m-A, which has been present in Spain since 2010, and HEV-3m-B, which appeared in 2014.

HEV-3c is overall the third most common subtype in Spain (4.1% of cases). In the east (Catalonia, Valencia and the Balearic Islands) and in the north-west (Galicia) of the country however, it is the second most frequent subtype. In the Netherlands, from 2009 to 2013, 68.8% of the HEV-3 cases grouped with HEV-3c compared to 22.2% with HEV-3f [21]. In Belgium, a study conducted from 2010 to 2017 showed that HEV-3c was the second main subtype (39.8%) after HEV-3f (50.7%) [14]. In South-western France, from 2003 to 2014, the HEV-3c subtype (19.9%) was also the second most represented after HEV-3f (73.6%) [16] and, in the same way, data from viruses collected in Italy, from 2000 to 2018 indicated that HEV-3c and HEV-3e followed HEV-3f as the second most common Italian subtypes [19].

While in Spain, the prevalence of HEV-3c subtype has not increased over time, a considerable increase of this subtype has been described in Belgium, France, Germany and the UK [5,11,14,17]. A study in France described an increase of HEV-3c from 2005–2010 to 2011–2016 [11]. An increase of the genetic HEV group 2 (the abch1 clade, which includes HEV-3c) was described in the UK first in the period from 2003 to 2012 [5], and subsequently, after a retrospective surveillance study in England and Wales from 2008 to 2017 [22]. In Germany, from 2006 to 2007, cases of HEV were predominantly HEV-3f and HEV-3a [18], while HEV-3c predominated from 2009 to 2016 [17].

The epidemiological and public health importance of the surveillance of HEV-3 subtype circulation is yet to be assessed. It has been suggested that a change of dominant HEV-3 subtype over time in the UK might be related to the rise of the number of cases due to population susceptibility to new variants [5]. The relative increase in the frequency of cases of a specific subtype might be related to the emergence of variants and the selection of viruses, or to the introduction of a new epidemiological factor, in the case of HEV-3, through a change in the food chain. In this sense, an increase in the number of cases in the UK was reported to be associated with pork products originating from outside the country and thus reflecting pork products related market issues [31]. This highlights the importance of making surveillance and control measures of HEV infection transnational and of closely watching new variants, such as the recently described HEV-3m, which is emerging in Spain and could be a variant of concern in the future.

There are some limitations of this study. First, as it is based on microbiological surveillance instead of epidemiological surveillance, epidemiological data are not available; second, the total coverage of the country might be affected by the fact that some ACs might not be continuously sending samples for HEV RNA typing to the reference laboratory.

Subtype and subcluster surveillance, together with the comprehensive epidemiological characterisation of clinical cases, including detailed information about the food eaten by the patient in the weeks preceding the appearance of the symptoms, could provide a useful tool for food tracking, to identify sources of transmission and to establishing control measures at the Spanish and European levels.

In summary, HEV-3f, present in all Spanish ACs, was the dominant subtype (88.3%) in Spain between 2009 and 2019, with no change in its level of occurrence over time. Three subclusters within this subtype were characterised for the first time in the current study: HEV-3f-B, HEV-3f-A1 and HEV-3f-A2. The recently described HEV-3m was the second most common HEV subtype, circulating in Spain at a frequency of over 7%. Two subclusters were identified: HEV-3m-A, which has been circulating in Spain since 2010, and HEV-3m-B, since 2014. HEV-3c was the third most frequent subtype in Spain (4.1%), and its proportion did not increase over time, contrary to what was observed in some countries in Europe.

Conclusions
Although the epidemiological and public health importance of the surveillance of HEV-3 subtype circulation is yet to be assessed, changes circulation patterns might be related to the increase of population susceptibility to recently introduced new variants. Surveillance of the subtypes and subclusters, and the comprehensive epidemiological characterisation of clinical cases, could provide a useful tool for food-tracking in these cases, identifying sources of transmission and contributing to the establishment of control measures at the national and European levels.
Acknowledgements

The authors thank the laboratory staff Sandra Arroyo, for preparing the samples. Members of the HEV Study Group provided the samples from which RNA was extracted for the molecular analyses carried out in this study: María Muñoz-Algarra (Hospital Puerta de Hierro, Majadahonda); Mario Jose Rodriguez (Hospital Ramon y Cajal); Sara Maria Quevedo Soriano (Hospital Severo Ochoa); Buenaventura Buendia (Hospital Universitario de la Princesa); Aitziber Aguinaga (Complejo Hospitalario de Navarra); Adelina Gimeno (Hospital General Universitario de Alicante); Leire Lopez (Hospital de Cruces); Francisco Javier Candel (Hospital San Carlos); Isabel Lopez (Hospital do Meixoeiro); Encarnación Ramírez de Arellano (Complejo Hospitalario Virgen Macarena); Roberto Alonso (Hospital General Universitario Gregorio Marañón); Alejandro Gonzalez (Hospital Universitario de Guadalajara); Alfredo Perez-Rivilla (Hospital 12 de Octubre); Mercedes Rodriguez (Hospital Universitario Central de Asturias, Materno infantil); Ana Saéz (Hospital Universitario Marqués de Valdecilla); Maria del Carmen Suarez (Hospital de Basurto); Julian Sanchez (Hospital de Mérida); Laura Merino (Hospital Virgen del Rocio); Jose Vicente Saz (Hospital Universitario Príncipe de Asturias); Dolores Montero Vega (Hospital Universitario la Paz); Laura Maria Molina (Hospital de Fuenlabrada); Matilde Trigo (Complejo Hospitalario de Pontevedra); Francisco Javier Candel (Hospital Clínico San Carlos); Asunción del Valle (Hospital de Cabueñas); Montserrat Ruiz (Hospital General Universitario de Elche); Lurdes Matas (Hospital Universitari Germans Trias i Pujol); Maria Mateo Maestre (Hospital Central de la Defensa Gomez Ulla); Cesar Gomez (Hospital Virgen de la Salud, Toledo); Araceli Hernandez (Hospital Universitario Insular of Gran Canaria); Natalia Montiel (Hospital Costa del Sol); Xavier Casal (Hospital Nosito Senyora de Merixell, Andorra); Estibaliz Ugalde (Hospital San Pedro); Jose Saavedra (Hospital General Juan Ramon Jimenez); Juan Garcia-Costa (Hospital Santa Maria Nai); Antonio Orduña (Hospital Clinico Universitario de Valladolid); Antoni Serra (Fundacion Hospital de Pontevedra); Maria Dolores Navarro (Hospital J.M. Morales Manacor); Maria Dolores Navarro (Hospital J.M. Morales Meseguer); Cristina Frau (Hospital General Universitario of Ciudad Real); Francisco Salva (Hospital Universitario Son Espases); Maite Lopez (Hospital Universitari Sant Joan D’Alacant); Encarnación Clavijo (Hospital Virgen de la Victoria); Fatima Lopez (Hospital de Móstoles); Maria Dolores Martin (Laboratorio BRSalud); Isabel Garcia Bermejo (Hospital Universitario de Getafe); Pedro Aguirre (Hospital Campo Arañuelo, Navalmaral de la Mata) and Alba Cebollero (Consorci Laboratori Intercomarcal).

Conflict of interest

None declared.

Authors’ contributions

Milagros Muñoz-Chimeno performed laboratory assays, sequence analysis and wrote the article. Silvia Barturen helped in laboratory and sequence analysis. Maira Alejandra Garcia-Lugo helped with the laboratory assays. Lucia Morago and Álvaro Rodríguez provided general technical assistance. Juan Carlos Galán, Alfredo Pérez-Rivilla, Mercedes Rodríguez, Rosario Millán, Manuel del Álamo, Roberto Alonso, Laura Molina and Aitziber Aguinaga sent samples for HEV analysis. Ana Avellón directed and coordinated the study and production of the manuscript.

Ethical statement

The study was based on routine HEV testing, did not involve any additional sampling or tests and stored irreversibly anonymised RNA extracts were used, so specific ethical approval was not required for this study.

Funding statement

CIBERESP contract for the first author

References

1. Adihoo C, Avellon A, Baylis SA, Ciccaglione AR, Couturier E, de Sousa R, et al. Hepatitis E virus: Assessment of the epidemiological situation in humans in Europe, 2014-2015. J Clin Virol. 2016;82:9-16. https://doi.org/10.1016/j.jcv.2016.06.010 PMID: 27393938
2. Purdy MA, Harrison TJ, Jameel S, Meng XJ, Okamoto H, Van der Poel WHM, et al., ICTV Report Consortium. ICTV Virus Taxonomy Profile: Hepheviridae. J Gen Virol. 2017;98(s1):2645-6. https://doi.org/10.1099/jgv.0.009940 PMID: 29022866
3. Smith DB, Simpmonds P, I佐pet J, Olivreira-Filho EF, Ulrich RG, Johne R, et al. Proposed reference sequences for hepatitis E virus subtypes. J Gen Virol. 2016;97(3):537-42. https://doi.org/10.1099/jgv.0.009393 PMID: 26743685
4. Spahr C, Knauf-Witzen T, Vahlenkamp T, Ulrich RG, Johne R. Hepatitis E virus and related viruses in wild, domestic and zo0 animals: A review. Zoosnes Public Health. 2018;85(6):11-29. https://doi.org/10.1111/zph.12405 PMID: 28946402
5. Iijaz S, Said B, Boxall E, Smit E, Morgan D, Tedder RS. Indigenous hepatitis E in England and Wales from 2003 to 2012: evidence of emerging novel phylotype of viruses. J Infect Dis. 2014;209(8):1222-8. https://doi.org/10.1093/infdis/jit652 PMID: 24273173
6. Zhao C, Ma Z, Harrison TJ, Feng R, Zhang C, Qiao Z, et al. A novel genotype of hepatitis E virus prevalent among farmed rabbits in China. J Med Virol. 2009;81(8):1371-9. https://doi.org/10.1002/jmv.21536 PMID: 19551838
7. Miura M, Inoue J, Tsuruoka M, Nishizawa T, Nagashima S, Takahashi M, et al. Full-length genomic sequence analysis of new subtype 3k hepatitis E virus isolates with 99.97% nucleotide identity obtained from two consecutive acute hepatitis E patients in a city in northeast Japan. J Med Virol. 2017;89(6):1116-20. https://doi.org/10.1002/jmv.24743 PMID: 27922191
8. De Sabato L, Leney P, Vrancken B, Bonfanti L, Ceglie L, Vaccari G, et al. Proposal for a new subtype of the zoonotic genotype 3 hepatitis E virus: HEV-3. Virus Res. 2016;228:7-14. https://doi.org/10.1016/j.virres.2016.02.010 PMID: 25421644
9. Smith DB, I佐pet J, Nicot F, Simmonds P, Jameel S, Meng XJ, et al. Update: proposed reference sequences for subtypes of hepatitis E virus (species Orthohepevirus A).J Gen Virol. 2020;101(7):692-8. https://doi.org/10.1099/jgv.0.001435 PMID: 32469300
10. Muñoz-Chimeno M, Forero JE, Echevarría JM, Muñoz-Bellido JL, Vázquez-López L, Morago L, et al. Full coding hepatitis E virus subtype 3 genome amplification method. J Virol Methods. 2016;230:18-23. https://doi.org/10.1016/j.jviromet.2016.01.004 PMID: 26784284
11. Nicot F, Jeanne N, Roulet A, Lefevbre C, Carcenac R, Manno M, et al. Diversity of hepatitis E virus genotype 3. Rev Med Virol. 2018;28(5):e1987. https://doi.org/10.1002/rmv.1987 PMID: 29939461
12. Nicot F, Dimeglio C, Migueures M, Jeanne N, Latour J, Abravanel F, et al. Classification of the Zoonotic Hepatitis E Virus Genotype 3 Into Distinct Subgenotypes. Front Microbiol. 2018;9:326. https://doi.org/10.3389/fmicb.2018.00326 PMID: 33584599
13. Subissi L, Peeters M, Lamoral S, Klamr S, Suin V, Van Gucht S. Subtype-specific differences in the risk of hospitalisation among patients infected with hepatitis E virus genotype 3 in Belgium, 2010-2016. Epidemiol Infect. 2019;147:8224. https://doi.org/10.1017/S0950268819001122 PMID: 31364564
14. Suin V, Klamr S, Hautse W, Vautier M, Jacques M, Abyady E, et al. Epidemiology and genotype 3 subtype dynamics of hepatitis E virus in Belgium, 2010 to 2017. Euro Surveill. 2019;24(10):1800141. https://doi.org/10.2807/1560-7917.ES.2019.24.10.1800141 PMID: 30862337
15. Brunl R, Villano U, Equestre M, Chionne P, Madonna E, Trandeva-Bankova D, et al. Hepatitis E virus genotype 3 subgenotypes causing acute hepatitis in Bulgaria, 2013-2015. PloS One. 2018;13(6):e0198045. https://doi.org/10.1371/journal.pone.0198045 PMID: 29879148
16. Lhomme S, Abravanel F, Dubois M, Chapuy-Regaud S, Sandres-Saune K, Mansuy JM, et al. Temporal evolution of the
distribution of hepatitis E virus genotypes in Southwestern France. Infect Genet Evol. 2015;35:50-5. https://doi.org/10.1016/j.meegid.2015.07.028 PMID: 26218544

17. Wang B, Harms D, Papp CP, Niendorf S, Jacobsen S, Lütgemeier M, et al. Comprehensive Molecular Approach for Characterization of Hepatitis E Virus Genotype 3 Variants. J Clin Microbiol. 2018;56(5):e01686-17. https://doi.org/10.1128/JCM.01686-17 PMID: 29514938

18. Wichmann O, Schimanski S, Koch J, Kohler M, Rothe C, Plentz A, et al. Phylogenetic and case-control study on hepatitis E virus infection in Germany. J Infect Dis. 2008;198(12):1732-41. https://doi.org/10.1086/593211 PMID: 18983248

19. Garbuglia AR, Bruni R, Villano U, Vairo F, Lapa D, Madonna E, et al. The Other Members Of The Hev Outbreak Working Group. Hepatitis E Outbreak in the Central Part of Italy Sustained by Multiple HEV Genotype 3 Strains, June-December 2019. Viruses. 2021;13(6):1159. https://doi.org/10.3390/v13061159 PMID: 34204376

20. Koot H, Hogema BM, Koot M, Molier M, Zaaijer HL. Frequent hepatitis E in the Netherlands without traveling or immunosuppression. J Clin Virol. 2015;62:38-40. https://doi.org/10.1016/j.jcv.2014.11.020 PMID: 25542468

21. Oeser C, Vaughan A, Said B, Ijaz S, Tedder R, Haywood B, et al. Epidemiology of Hepatitis E in England and Wales: A 10-Year Retrospective Surveillance Study, 2008-2017. J Infect Dis. 2019;220(5):802-10. https://doi.org/10.1093/infdis/jiz207 PMID: 3107958

22. Rivero-Juarez A, Aguado R, Lopez-Lopez P, Sanchez-Frias M, Fias M, Briceno J, et al. Prevalence of hepatitis E virus infection in liver donors in Spain. Clin Microbiol Infect. 2018;24(12):1218-9. https://doi.org/10.1016/j.cmi.2018.06.030 PMID: 30017970

23. García N, Hernández M, Gutierrez-Boada M, Valero A, Muñoz-Chimeno M, et al. Occurrence of Hepatitis E Virus in Pigs and Pork Cuts and Organs at the Time of Slaughter, Spain, 2017. Front Microbiol. 2020;11:137. https://doi.org/10.3389/fmicb.2020.00137 PMID: 3211756

24. Caballero-Gómez J, Jiménez-Ruíz S, Lopez-Lopez P, Vicente J, Rísalde MA, Cano-Terriza D, et al. Emergent subtype of hepatitis E virus genotype 3 in wild boar in Spain. Transbound Emerg Dis. 2019;66(5):1803-8. https://doi.org/10.1111/tbed.13251 PMID: 31127865

25. Lhomme S, Gallian P, Dimeglio C, Assal A, Abravelan F, Tiberghien P, et al. Viral load and clinical manifestations of hepatitis E virus genotype 3 infections. J Viral Hepat. 2019;26(9):1139-42. https://doi.org/10.1111/jvh.13128 PMID: 31099059

26. Mulder AC, Kroneman A, Franz E, Vennema H, Tulen AD, Takkinnen J, et al. Members Of HEVnet. HEVnet: a One Health, collaborative, interdisciplinary network and sequence data repository for enhanced hepatitis E virus molecular typing, characterisation and epidemiological investigations. Euro Surveill. 2019;24(10):1800407. https://doi.org/10.2807/1560-7917.ES.2019.24.10.1800407 PMID: 30863334

27. Lhomme S, Abravelan F, Dubois M, Sandres-Saune K, Mansuy JM, Rostaing L, et al. Characterization of the polyproline region of the hepatitis E virus in immunocompromised patients. J Virol. 2014;88(20):12017-25. https://doi.org/10.1128/JVI.01625-14 PMID: 25100839

28. Murdock AC, Kroneman A, Franz E, Vennema H, Tulen AD, Takkinnen J, et al. Members Of HEVnet. HEVnet: a One Health, collaborative, interdisciplinary network and sequence data repository for enhanced hepatitis E virus molecular typing, characterisation and epidemiological investigations. Euro Surveill. 2019;24(10):1800407. https://doi.org/10.2807/1560-7917.ES.2019.24.10.1800407 PMID: 30863334

29. Lhomme S, Gallian P, Dimeglio C, Assal A, Abravelan F, Tiberghien P, et al. Viral load and clinical manifestations of hepatitis E virus genotype 3 infections. J Viral Hepat. 2019;26(9):1139-42. https://doi.org/10.1111/jvh.13128 PMID: 31099059

30. Wang H, Castillo-Contreras R, Saguti F, López-Olvera JR, Karlsson M, Mentabarre G, et al. Genetically similar hepatitis E virus strains infect both humans and wild boars in the Barcelona area, Spain, and Sweden. Transbound Emerg Dis. 2019;66(2):978-85. https://doi.org/10.1111/tbed.13115 PMID: 30957744

31. Said B, Usdin M, Warburton F, Ijaz S, Tedder RS, Morgan D. Pork products associated with human infection caused by an emerging phylotype of hepatitis E virus in England and Wales. Epidemiol Infect. 2017;145(12):2417-23. https://doi.org/10.1017/S0950268817003388 PMID: 28756783

License, supplementary material and copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence and indicate if changes were made.

Any supplementary material referenced in the article can be found in the online version.

This article is copyright of the authors or their affiliated institutions, 2022.